Last reviewed · How we verify
Eosinophilic asthma
Approved treatments
- Fasenra · AstraZeneca
Fasenra works by binding to the interleukin-5 receptor on eosinophils, triggering their destruction. - Caricide · Pfizer
- Nucala · GSK
Nucala works by binding to interleukin-5, a protein that stimulates the production of eosinophils. - Cinqair · Teva Respiratory Llc
Cinqair works by blocking the action of interleukin-5, a protein that promotes the production of eosinophils, which contribute to inflammation in the airways. - Prelone · Generic (originally Schering)
- prednisolon · Hannover Medical School
- Nucala · Mayo Clinic
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Eosinophilic asthma patent landscape — cliff calendar, originator estates, attackable patents
- Eosinophilic asthma treatment landscape brief
- Eosinophilic asthma treatment updates RSS
Frequently asked questions about Eosinophilic asthma
What drugs treat Eosinophilic asthma?
Tracked treatments include Fasenra, Caricide, Nucala, Cinqair, Prelone, prednisolon.
What is the treatment for Eosinophilic asthma?
Standard treatment for Eosinophilic asthma includes Fasenra, Caricide, Nucala, Cinqair, Prelone. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Eosinophilic asthma patent cliff · Eosinophilic asthma CI report
- Treatment: Fasenra · AstraZeneca
- Treatment: Caricide · Pfizer
- Treatment: Nucala · GSK
- Treatment: Cinqair · Teva Respiratory Llc
- Treatment: Prelone · Generic (originally Schering)
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing